Evidence map›Paper›PMID 34109013›Full record

ArticleJournal of medical devices2018

Development of an alveolar transbronchial catheter for concurrent fiber optics based imaging and fluid delivery.

Nathan Knighton, Brian Cottle, Veronique Dentan, Tom Vercauteren, Ahsan Akram, Annya Bruce, Kevin Dhaliwal, Robert Hitchcock

Open access · greenAbstract read
In one paragraph

Article in Journal of medical devices, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Nathan KnightonDepartment of Bioengineering, University of Utah, 36 S Wasatch Dr., Salt Lake City UT, 84112.
Brian CottleDepartment of Bioengineering, University of Utah, 36 S Wasatch Dr., Salt Lake City UT, 84112.
Veronique DentanMauna Kea Technologies, 9, rue d'Enghien, Paris, 75010, France.
Tom VercauterenUniversity College London, Wellcome / EPSRC Centre for Interventional and Surgical Sciences, Charles Bell House, 43-45 Foley Street, London W1W 7TS, United Kingdom.
Ahsan AkramEPSRC Proteus Hub, MRC Centre for Inflammation Research, The University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom.
Annya BruceEPSRC Proteus Hub, MRC Centre for Inflammation Research, The University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom.
Kevin DhaliwalEPSRC Proteus Hub, MRC Centre for Inflammation Research, The University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom.
Robert HitchcockDepartment of Bioengineering, University of Utah, 36 S Wasatch Dr., Salt Lake City UT, 84112.
University of Utah · USCentre for Inflammation Research · GBMauna Kea Technologies (France) · FRThe Queen's Medical Research Institute · GBUniversity College London · GBUniversity of Edinburgh · GB

Funding

Medical Research Council MR/J010901/1
6 · The paper itself

Abstract

Optical molecular imaging is an emerging field and high resolution optical imaging of the distal lung parenchyma has been made possible with the advent of clinically approved fiber based imaging modalities. However, currently, there is no single method of allowing the simultaneous imaging and delivery of targeted molecular imaging agents. The objective of this research is to create a catheterized device capable of fulfilling this need. We describe the rationale, development, and validation in ex vivo ovine lung to near clinical readiness of a triple lumen bronchoscopy catheter that allows concurrent imaging and fluid delivery, with the aim of clinical use to deliver multiple fluorescent compounds to image alveolar pathology. Using this device, we were able to produce high-quality images of bacterial infiltrates in ex-vivo ovine lung within 60 seconds of instilling a single microdose of (<100 mcgs) imaging agent. This has many advantages for future clinical usage over the current state of the art.

Identifiers

PMID34109013
PMCPMC7610938
OpenAlexW2810814773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.